10 completed, 8 active not recruiting, 8 recruiting, 1 not yet recruiting. 27 Phase 3.
By phase and status
Follow orforglipron: new trials by email Literature Review of orforglipron trials Research Report on orforglipron
Trials (filtered) newest first · largest first
All 27 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems Orforglipron, Placebo - Obesity, Overweight Phase 3 Not yet recruiting 192 2026-12-01 2026-10-13
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity Orforglipron, Placebo - Overweight, Prediabetic State Phase 3 Recruiting 2001 2026-08-26 2026-11-05
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting Orforglipron - Diabetes Mellitus, Type 2, Diabetes Melletus Phase 3 Recruiting 130 2026-07-15 2026-10-08
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes Orforglipron, Dulaglutide - Diabetes Mellitus, Type 2 Phase 3 Recruiting 170 2026-07-08 2026-11-05
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) Orforglipron, Placebo - Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease Phase 3 Recruiting 7140 2025-12-01 2026-11-04
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease Orforglipron, Placebo - Peripheral Arterial Disease Phase 3 Recruiting 1205 2025-10-31 2026-11-04
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight Orforglipron, Placebo - Urinary Incontinence,Stress Phase 3 Recruiting 1000 2025-09-30 2026-11-04
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee Orforglipron, Placebo - Osteoarthritis Phase 3 Active not recruiting 800 2025-09-15 2026-10-08
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes Orforglipron, Placebo - Obesity, Overweight Phase 3 Active not recruiting 600 2025-05-19 2026-04-20
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes Orforglipron, Placebo - Obesity, Overweight Phase 3 Active not recruiting 1400 2025-05-15 2026-07-31
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity Orforglipron, Placebo - Obesity, Overweight Phase 3 Active not recruiting 800 2025-05-15 2026-07-29
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 Orforglipron, Placebo - Hypertension, Overweight or Obesity Phase 3 Active not recruiting 487 2025-04-30 2026-05-29
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) Orforglipron, Placebo - Hypertension Phase 3 Active not recruiting 974 2025-04-30 2026-05-29
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 Orforglipron, Placebo - Hypertension Phase 3 Active not recruiting 487 2025-04-30 2026-05-29
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities Orforglipron, Placebo - Obesity, Overweight Phase 3 Recruiting 150 2024-11-18 2026-11-04
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) Orforglipron, Placebo - Obesity, Overweight Phase 3 Recruiting 125 2024-11-18 2026-11-04
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight Orforglipron, Placebo - OSA, Overweight or Obesity Phase 3 Completed 712 2024-10-22 2026-09-14
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) Orforglipron, Placebo - Obesity, Overweight Phase 3 Completed 376 2024-09-13 2026-06-04
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin Orforglipron, Dapagliflozin - Type 2 Diabetes Phase 3 Completed 962 2024-01-10 2026-10-16
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor Orforglipron, Placebo - Type 2 Diabetes Phase 3 Completed 546 2023-11-10 2026-10-01
Showing 20 of 27. Sign in to see all of them.
Conditions studied Obesity (14) · Overweight (14) · Diabetes Mellitus, Type 2 (11) · Hypertension (3) · Nutrition Disorders (2) · Renal Insufficiency, Chronic (2) · Arthritis (1) · Behavior (1) · Body Weight Changes (1) · Cardiovascular Diseases (1) · Endocrine System Diseases (1) · Fasting (1) · Feeding Behavior (1) · Glucose Metabolism Disorders (1) · Heart Diseases (1)
Sponsors Eli Lilly and Company (27)
Countries United States (22) · Japan (21) · China (20) · Puerto Rico (15) · Argentina (13) · Germany (13) · Czechia (12) · India (12) · Mexico (11) · Spain (10) · Brazil (9) · Poland (9) · South Korea (9) · Greece (7) · Taiwan (7)
Results publications PMID 42577069 , PMID 40544435 , PMID 40960239 , PMID 41275875 , PMID 41765029 , PMID 42120723 , PMID 42251769 , PMID 42259339 , PMID 42383207 , PMID 42607698 , PMID 42750540 , PMID 42815506 , PMID 42830762
NIH funding 2025 (8) , 2023 (2)